Pamela Perry

1.3k total citations
34 papers, 852 citations indexed

About

Pamela Perry is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, Pamela Perry has authored 34 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 7 papers in Clinical Psychology and 6 papers in Pharmacology. Recurrent topics in Pamela Perry's work include Schizophrenia research and treatment (20 papers), Bipolar Disorder and Treatment (8 papers) and Treatment of Major Depression (6 papers). Pamela Perry is often cited by papers focused on Schizophrenia research and treatment (20 papers), Bipolar Disorder and Treatment (8 papers) and Treatment of Major Depression (6 papers). Pamela Perry collaborates with scholars based in United States, Denmark and Austria. Pamela Perry's co-authors include Raymond Sanchez, Robert D. McQuade, William H. Carson, John M. Kane, B. Johnson, Ross A. Baker, Na Jin, W. Wolfgang Fleischhacker, Anna Eramo and Timothy Peters-Strickland and has published in prestigious journals such as The Lancet, Neurology and The British Journal of Psychiatry.

In The Last Decade

Pamela Perry

32 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pamela Perry United States 15 655 154 133 127 122 34 852
Jitschak G. Storosum Netherlands 17 314 0.5× 139 0.9× 238 1.8× 47 0.4× 34 0.3× 26 688
Steve Offord United States 14 459 0.7× 72 0.5× 155 1.2× 136 1.1× 35 0.3× 19 662
Rita A. Shaughnessy United States 13 317 0.5× 70 0.5× 106 0.8× 65 0.5× 49 0.4× 30 671
David A. Curson United Kingdom 15 678 1.0× 111 0.7× 238 1.8× 238 1.9× 68 0.6× 21 804
M J Woyshville United States 10 538 0.8× 62 0.4× 130 1.0× 23 0.2× 118 1.0× 10 704
Susan N. Legacy United States 8 377 0.6× 50 0.3× 101 0.8× 94 0.7× 26 0.2× 9 495
Lara McCartney Australia 5 402 0.6× 48 0.3× 76 0.6× 102 0.8× 31 0.3× 5 495
Douglas Vanderburg United States 11 336 0.5× 105 0.7× 138 1.0× 39 0.3× 64 0.5× 19 534
Michael D. Teehan Canada 12 312 0.5× 87 0.6× 119 0.9× 68 0.5× 27 0.2× 22 526
M. Jackuelyn Harris United States 8 381 0.6× 62 0.4× 99 0.7× 91 0.7× 15 0.1× 10 553

Countries citing papers authored by Pamela Perry

Since Specialization
Citations

This map shows the geographic impact of Pamela Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Perry more than expected).

Fields of papers citing papers by Pamela Perry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Perry. The network helps show where Pamela Perry may publish in the future.

Co-authorship network of co-authors of Pamela Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Perry. A scholar is included among the top collaborators of Pamela Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Perry. Pamela Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Krystal, John H., John M. Kane, Christoph U. Correll, et al.. (2022). Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet. 400(10369). 2210–2220. 77 indexed citations
3.
Whitmore, Laura M., et al.. (2022). Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic (P2-8.007). Neurology. 98(18_supplement). 1 indexed citations
4.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2018). The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. Journal of Affective Disorders. 241. 425–432. 15 indexed citations
5.
Devinsky, Orrin, Jordyn M. Boesch, Sofía Cerdá-González, et al.. (2018). A cross-species approach to disorders affecting brain and behaviour. Nature Reviews Neurology. 14(11). 677–686. 20 indexed citations
6.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder. The Journal of Clinical Psychiatry. 78(3). 324–331. 72 indexed citations
7.
Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. Journal of Affective Disorders. 227. 649–656. 21 indexed citations
8.
9.
Davis, Lori L., et al.. (2016). Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain and Behavior. 6(10). e00520–e00520. 19 indexed citations
10.
Malla, Ashok, et al.. (2016). The effect of brexpiprazole in adult outpatients with early-episode schizophrenia. International Clinical Psychopharmacology. 31(6). 307–314. 13 indexed citations
11.
Weisler, Richard H., et al.. (2016). Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. Journal of Affective Disorders. 204. 40–47. 13 indexed citations
12.
Peters-Strickland, Timothy, Cathy Zhao, Pamela Perry, et al.. (2016). Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectrums. 21(6). 460–465. 7 indexed citations
13.
Citrome, Leslie, et al.. (2016). The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. International Clinical Psychopharmacology. 31(4). 192–201. 49 indexed citations
14.
Kane, John M., Raymond Sanchez, Ross A. Baker, et al.. (2015). Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical Schizophrenia & Related Psychoses. 9(2). 79–87. 15 indexed citations
15.
Peters-Strickland, Timothy, Ross A. Baker, Robert D. McQuade, et al.. (2015). Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. Schizophrenia. 1(1). 15039–15039. 12 indexed citations
16.
Fleischhacker, W. Wolfgang, Ross A. Baker, Anna Eramo, et al.. (2014). Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. Schizophrenia Research. 159(2-3). 415–420. 21 indexed citations
17.
Kane, John M., Timothy Peters-Strickland, Ross A. Baker, et al.. (2014). Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia. The Journal of Clinical Psychiatry. 75(11). 1254–1260. 84 indexed citations
18.
Perry, Pamela, et al.. (2013). The relation of maternal fluid balance to offspring passive immunity. Physiology & Behavior. 122. 155–158. 3 indexed citations
19.
Fleischhacker, W. Wolfgang, Pamela Perry, Raymond Sanchez, et al.. (2013). Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia. Value in Health. 16(7). A550–A550. 1 indexed citations
20.
Wright, Curtis, et al.. (2004). Hyperalgesia in Outpatients with Dermal Injury: Quantitative Sensory Testing Versus a Novel Simple Technique. Pain Medicine. 5(2). 162–167. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jitschak G. Storosum Breakdown of academic impact, for papers by Steve Offord Breakdown of academic impact, for papers by Rita A. Shaughnessy Breakdown of academic impact, for papers by David A. Curson Breakdown of academic impact, for papers by M J Woyshville Breakdown of academic impact, for papers by Susan N. Legacy Breakdown of academic impact, for papers by Lara McCartney Breakdown of academic impact, for papers by Douglas Vanderburg Breakdown of academic impact, for papers by Michael D. Teehan Breakdown of academic impact, for papers by M. Jackuelyn Harris
Rankless by CCL
2026